Epidemiological studies have revealed that schizophrenia and immune diseases co-occur 38 in the general population at higher than expected rates. Here, we evaluated whether the 39 epidemiologic correlation between immune diseases and schizophrenia might be explained by 40 shared genetic risk factors. We used data from a large genome-wide association study (GWAS) 41 of schizophrenia (N=35,476 cases and 46,839 controls) to compare the genetic architecture of 42 schizophrenia to 19 immune diseases. First, we evaluated the association with schizophrenia of 43 581 variants previously reported to be associated with immune diseases at genome-wide 44 significance. Next, we investigated genome-wide sharing of common variants using polygenic 45 risk scores for immune diseases. We identified nine variants with potential pleiotropic effects, 46 located in regions associated with both schizophrenia and autoimmune disease. Five of these 47 51 ulcerative colitis (p=4.3x10 -4 ). Genetic correlation between these immune diseases and 52 schizophrenia, estimated using cross-trait LD Score regression, ranged from 0.10 to 0.18. We 53 also observed suggestive evidence of sex-dependent genetic correlation between schizophrenia 54 and multiple sclerosis (interaction p=0.02), with genetic risk scores for multiple sclerosis 55 associated with greater risk of schizophrenia among males but not females. Our findings reveal 56
variants were located outside of the human leukocyte antigen region, and mapped to genes with 48 known roles in calcium signaling. Polygenic risk scores revealed significant genetic overlap with 49 schizophrenia for narcolepsy (p=4.1x10 -4 ), primary biliary cirrhosis (p=1.4x10 -8 ), psoriasis 50 (p=3.6x10 -5 ), systemic lupus erythematosus (p=2.2x10 -8 ), type 1 diabetes (p=2.0x10 -6 ), and Introduction 76 Despite recent advances in identifying key biomarkers and genetic loci for 77 schizophrenia, its pathophysiology remains poorly understood (1, 2). One interesting 78 epidemiological observation is that the risk of developing an immune-mediated disease is 79 increased among patients with schizophrenia (3-5), and vice versa (6, 7). Here, we use the 80 term immune disease to broadly encompass both autoimmune and inflammatory disorders.
81
While there are discrepancies among studies regarding which immune diseases are most 82 strongly correlated with schizophrenia, there is converging evidence that these diseases co-83 occur at a greater rate than is expected by chance (3-7). A notable exception is rheumatoid 84 arthritis (RA), where a consistent inverse association with schizophrenia has been observed (5, 85 8).
86
Genetic factors have long been proposed as an explanation for the differing prevalence 87 of immune diseases among patients with schizophrenia compared to the general population (5, 88 6). The recently discovered role of complement component 4 (C4) variation in schizophrenia (9) 89 provides a compelling illustration of a shared genetic mechanism in the development of immune 90 and psychiatric disorders. Genetic variants conferring increased C4 expression protect against 91 developing systemic lupus erythematosus (SLE), possibly by increased tagging of apoptotic 92 cells -which are the trigger for autoantibody development in SLE -leading to more effective 93 clearance by macrophages (10). The same genetic mechanism increases the risk of developing 94 schizophrenia, likely by increased tagging of neuronal synapses for elimination by microglia 95 leading to excessive synaptic pruning (9) . Similar shared genetic mechanisms may occur 96 throughout the genome, with cellular manifestations in immune cells and neurons influencing 97 the development of immune and psychiatric disorders, respectively. Recently, we found that 98 susceptibility to schizophrenia does not appear to be driven by the broad set of loci harboring 99 immune genes (11). However, not all genetic variants conferring risk of immune disease fall within immune loci. Here, we evaluated whether common genetic variants influencing the risk of 101 19 different immune diseases may also be involved in schizophrenia.
102
Our cross-disorder genetic approach is supported by recent successes in identifying 103 shared genetic risk variants (pleiotropy) across a variety of human diseases (12-17). While the 104 effect sizes identified in cross-disorder studies are often modest, they have the potential to yield 105 significant insights into disease etiology. For instance, cross-trait genetic analyses have shed 106 new light on cardiovascular disease and lipid biology -and shifted attention away from HDL as 107 a potential treatment target -by demonstrating that increased HDL cholesterol levels do not 108 reduce the risk of myocardial infarction (14). In psychiatry cross-disorder analyses have 109 identified significant pleiotropy between schizophrenia, bipolar disorder, and major depressive 110 disorder, indicating that these diseases are not as distinct at a pathophysiological level as 111 current diagnostic criteria suggest (12, 13) . While previous studies have investigated genetic 112 correlation between schizophrenia and immune disorders, results have been inconsistent (S1 113   Table) . Genetic correlation has been reported between schizophrenia and Crohn's disease (18-114 20), multiple sclerosis (21), rheumatoid arthritis (18, 19) , systemic lupus erythematosus (19, 20) , 115 type 1 diabetes (18), and ulcerative colitis (19, 20) in some studies, but not in others (8, 13, 16, Pouget, JG et al. 7
18 HLA variants) associated with any immune disease at genome-wide significance. We refer to 152 these variants as immune risk variants.
154
Genome-wide significant immune disease loci are associated with schizophrenia 155
To evaluate the association of immune risk variants with schizophrenia, we used 156 previously published findings from a GWAS conducted by the Schizophrenia Working Group of 157 the Psychiatric Genomics Consortium (1, 11) . This GWAS represented a meta-analysis of 52 158 cohorts, comprising a total of 35,476 cases and 46,839 controls, and the full dataset is referred 159 to here as the SCZ-52 study. We considered SNPs associated with schizophrenia at p<8.6x10 -5 160 (Bonferroni correction for 581 tests, 563 non-HLA and 18 HLA variants) to have pleiotropic 161 effects. Given the size of the schizophrenia GWAS, we had over 80% power to detect 162 pleiotropic SNPs assuming an OR≥1.12 in schizophrenia. Five immune risk variants showed 163 potential pleiotropic effects, with the risk allele for immune disease also conferring risk for 164 schizophrenia ( Table 3) . These variants have been previously implicated in CRO (rs6738825, 165 rs13126505, rs1734907 (26, 27)), MS (rs7132277 (28)), and CEL (rs296547 (29)). To evaluate 166 the pleiotropic potential of these variants, we compared the genetic architecture of the region 167 using regional plots (S1 Fig) Fig 1) . The four HLA variants showing potential pleiotropic effects in 191 schizophrenia were the strongest HLA risk variants for alopecia (HLA-DRB1 #37 Asn), CEL 192 (HLA-DQB1 #74 Ala), PSC (HLA-B*08:01), and SJO (HLA-DQB1*02:01). There was very low 193 LD between these four HLA variants and rs1233578, the strongest associated variant in the 194 region in schizophrenia (r 2 =0.04 -0.20, Table 2 ). The presence of HLA-DRB1 #37 Asn 195 conferred a protective association in both alopecia and schizophrenia, but the remaining HLA 196 variants showed the opposite direction of effect in schizophrenia compared to immune disease 197 ( Fig 1) .
199

Polygenic risk for six immune diseases is associated with schizophrenia 200
Our immune risk variant set captured only those variants associated with immune 201 diseases at genome-wide significance in current GWASs. Given their polygenicity, there are 100s to 1,000s of additional variants associated with each immune disease which have not yet 203 been identified (31). To evaluate sharing of risk alleles between immune diseases and 204 schizophrenia using a broader set of variants, we used PRS (22, 24) and LDSC (16).
205
For each of the 14 immune diseases with available genome-wide summary statistics, we 206 constructed genetic risk scores (GRSs) at a range of p-value thresholds (p T ) as in previous 207 studies (12) and tested for the association of these GRSs with schizophrenia in a refined subset 208 of the SCZ-52 study (17,000 cases and 20,655 controls) which excluded samples shared with 209 the immune disease GWASs. To benchmark our findings in immune diseases, we also analyzed 210 human height (32) and included previously published PRS results for bipolar disorder (12). We 211 considered immune diseases with PRS p<0.002 at any p T to show significant genetic overlap 212 with schizophrenia (Bonferroni correction for 14 immune diseases tested in both sexes, 213 0.05/(14*2)=0.002). Importantly, commonly used goodness-of-fit estimates obtained from PRS 214 (such as β GRS and Nagelkerke's pseudo-R 2 ) lack meaningful interpretation and cannot be 215 compared across studies (33). For these reasons we used β GRS to interpret the direction of 216 effect (i.e. positive or negative correlation), but not to interpret or compare the degree of genetic 217 sharing between immune diseases and schizophrenia. For further details of our PRS approach, 218 see Materials and Methods.
219
Using PRS, we had over 80% power to detect genetic covariance with schizophrenia 220 ranging from 0.02-0.03 for most of the immune diseases, although some showed less than 80% 
222
As previously described, bipolar disorder PRSs were significantly associated with 223 schizophrenia (p<1x10 -50 at p T <1) (12) . Surprisingly, human height PRSs were also significantly 224 associated with schizophrenia (p=1x10 -11 at p T <1, S2 Table) . Height was analyzed as a 225 negative control based on its previously reported lack of genetic correlation with schizophrenia 226 using LDSC (16). Using PRS, we observed that genetic liability for increased height protected Pouget, JG et al. 10 against schizophrenia (β GRS =-0.11 at p T <1). The significant inverse association of height PRSs 228 with schizophrenia case-status we observed may reflect the greater sensitivity of this approach 229 to subtle population stratification, sample sharing, and/or true genetic overlap.
230
Genetic scores including the HLA region were significant for CEL, NAR, PBC, PSO, RA, 231 SLE, SSC, T1D, and UC (p<0.002 at multiple p T , S3 Table) . Height was not included in these 232 analyses, given that HLA variants have not been previously reported in GWAS of this phenotype 233 (32) . With the exception of CEL (β GRS ≈ -0.04 at p T <5x10 -8 , 1x10 -4 , and 1x10 -3 ), all immune 234 diseases exhibited a positive association with schizophrenia case-status (all β GRS >0, S3 Table) .
235
For CEL, RA, SLE, and SSC only those PRSs constructed using the most stringent p-value 236 cutoffs (5x10 -8 , 1x10 -4 , 1x10 -3 ) were significantly associated with schizophrenia. To evaluate 237 whether the HLA region alone was driving the observed genetic sharing, we constructed PRSs 238 excluding this region. After excluding HLA variants, genetic scores for NAR, PBC, PSO, SLE, 239 T1D, and UC remained significantly associated with schizophrenia (S5 Fig, S2 Table) . Because 240 the genetic overlap between these six immune diseases and schizophrenia was not driven by a 241 single HLA variant of large effect, we focused on these findings for the remainder of our 242 analyses.
243
Given the potential sensitivity of PRS to artificial genetic overlap highlighted in our 244 analysis of height, we wanted to assess whether cryptic sample sharing between the immune 245 and schizophrenia GWASs could be driving the shared genetic liability that we observed. To do 246 this, we conducted leave-half-out analyses. If the observed genetic overlap was driven by 247 samples shared between certain schizophrenia cohorts and the immune disease GWASs, the 248 PRS association should not be consistently observed across subsamples leaving out half of the 249 schizophrenia cohorts. Across 1,000 subsamples (N cases ranging from 3,985-13,074) leaving out 250 a randomly selected 14 cohorts, we observed a high proportion of subsamples with PRSs 251 significantly associated with schizophrenia (p<0.05 at p T <1) for height (0.99), NAR (0.72), PBC (0.95), PSO (0.84), SLE (0.97), T1D (0.95), and UC (0.70) suggesting our findings were not 253 driven by sample sharing.
254
To further validate our PRS results we applied LDSC, an independent method for 255 estimating genome-wide genetic correlation between traits that is robust to sample sharing (16), 256 using summary statistics from the 49 European-ancestry cohorts in the SCZ-52 study (31,335 257 cases and 38,765 controls) (1). Unlike PRS, LDSC provides an interpretable and comparable 258 estimation of genetic sharing between two traits in the form of genetic correlation (r g ) values.
259
Notably, LDSC is less sensitive than PRS and is not robust when applied to genetic data 260 obtained from specialty chips (e.g. Immunochip) (16). Given that this was a secondary analysis, 261 we considered immune diseases with r g p<0.05 to show significant genetic overlap with 262 schizophrenia.
263
As expected, our positive control (bipolar disorder) showed significant genetic overlap 264 with schizophrenia (r g =0.75±0.05, p=8.5x10 -60 ; Fig 2, S4 Table) . In contrast to our PRS results, 265 but in agreement with previous findings (16), our negative control (height) showed no such Table) indicating the association of PRSs for these diseases 269 was not driven by shared samples. Notably, genetic correlations for PSO and SLE did not 270 survive correction for the 14 tests performed (S4 Table) . We also observed significant genetic 271 overlap with schizophrenia for NAR and T1D using LDSC, with the caveat that these datasets 272 were genotyped using Immunochip and did not survive multiple testing correction (Fig 2, S4 273 Table) . Overall, LDSC provided consistent results for the six immune diseases showing 274 significant genetic sharing with schizophrenia by PRS. Interestingly, both CRO and IBD showed 275 significant genetic correlation with schizophrenia using LDSC (r g =0. Table) , while PRS for these diseases were not significant (S2 Pouget, JG et al. 12   Table) . The genetic correlations observed between immune diseases and schizophrenia were 278 moderate, with r g values about a fifth of that previously reported for bipolar disorder, and a 279 quarter of that for major depressive disorder (16).
281
Exploration of sex-dependent genetic correlation between schizophrenia and immune 282 diseases 283 Given the significant sex bias of autoimmune diseases, with women at greater risk 284 overall (34), we hypothesized that there may be sex-dependent genetic overlap between 285 schizophrenia and some immune-mediated diseases. We therefore performed sex-stratified 286 PRS, testing the association of height and immune disease GRSs with schizophrenia separately 287 in males and females of the SCZ-52 study. Genetic scores for height showed significant 288 association with schizophrenia in both males and females. Three of the immune diseases (PBC, 289 PSO, T1D) with significant main effects showed sex-dependent effects, with greater signal 290 among males (S5 Table) . Additionally, although genetic scores for MS were not significantly 291 associated with schizophrenia in the total sample there was significant association among 292 males (R 2 =0.03, p=1.26x10 -3 at p T <1; S5 Table) .
293
Given the greater statistical power for the male subset of the schizophrenia GWAS, we 294 performed simulations by selecting random subsamples of male cases and controls equal in 295 size to the female sample (5,321 cases and 9,094 controls). If the stronger genetic overlap 296 between schizophrenia and MS, PBC, PSO, and T1D among males was driven by the larger 297 sample size rather than a true sex-dependent effect, there should be no consistent association 298 of PRSs with schizophrenia in these subsamples. Across 1,000 subsamples, the proportion with 299 significant PRS (p<0.002 at p T <1) was high for PBC (0.94) and T1D (0.87), suggesting our 300 finding of a greater pleiotropic effect among males for these diseases was not driven solely by 301 lower statistical power among females; this was not the case for PSO (0.59) or MS (0.21).
Next, we performed formal statistical tests for an interaction between sex and genetic 303 scores for these four immune diseases. We observed a nominally significant interaction for MS 304 (p<0.05 at several p T ; S5 Table) , noting that this finding did not survive correction for multiple 305 testing. The remaining immune diseases did not show significant sex interactions, although the 306 direction of effect was consistent with a greater pleiotropic effect in males (S5 Table) . 
318
Within the HLA region, we identified four potentially pleiotropic variants. An important 319 caveat is that these four variants were not the top SNPs in their respective regions of 320 association with schizophrenia, and were not primary drivers of the MHC association in 321 schizophrenia in stepwise conditional analyses (9). Therefore, the biological significance of 322 these particular HLA variants in schizophrenia is likely limited.
323
Using PRS we observed shared genetic liability with schizophrenia for six immune 324 diseases (NAR, PBC, PSO, SLE, T1D, and UC), all of which have been previously reported to 325 co-occur with schizophrenia (3, 5, 37). Thus, currently available genetic data suggest that 326 shared genetic risk may contribute to the co-occurrence of these immune diseases in schizophrenia -particularly PBC, PSO, SLE, and UC, which also showed robust genetic 328 correlation with schizophrenia using LDSC. The magnitude of genetic correlations (r g values) 329 observed between these immune diseases and schizophrenia was about a fifth of that 330 previously reported for bipolar disorder, and a quarter of that for major depressive disorder (16).
331
Possible explanations for this sharing of genetic risk include the presence of a hidden subgroup 332 of "autoimmune-like" schizophrenia cases and/or sharing of specific biological pathways 333 between schizophrenia and these particular immune diseases.
334
To our knowledge, this is the first time that sex-dependent genetic correlation with 335 immune diseases has been investigated in schizophrenia. We found nominal evidence of male-336 specific genetic correlation for MS, and a stronger pleiotropic effect among males for PBC, 337 PSO, and T1D although the latter were not statistically significant. Interestingly, animal studies 338 indicate that sex hormones have opposing effects on predisposition to schizophrenia and 339 autoimmunity; estrogen has been reported to protect against the development of schizophrenia 340 (38), while androgens appear to protect against the development autoimmune diseases (39, 341 40). We emphasize that our sex-dependent findings require validation in independent samples.
342
If replicated, one possibility is that sex hormones modulate pathogenesis among genetically 343 vulnerable individuals, making males more likely to develop schizophrenia and females more 344 likely to develop autoimmune diseases.
345
Our work was subject to several important limitations. First, PRSs for human height -346 analyzed as a negative control -showed stronger association with schizophrenia than any of 347 the immune diseases. An inverse epidemiological relationship between height and 348 schizophrenia has been reported (41, 42), consistent with our PRS findings. The reasons for the 349 discrepancy between PRS and LDSC, which showed no genetic correlation between height and 350 schizophrenia (as previously reported (16)) are unclear. One possibility is that PRS, which uses 351 individual-level genotype data as opposed to summary statistics, is a more sensitive method to 352 detect genome-wide sharing of risk alleles. If this is the case, it raises a broader question regarding how much genetic overlap is expected across complex traits in general using the PRS 354 approach. An alternative explanation that must be considered is that PRS may be more 
Materials and Methods
396
Samples and quality control 397
We used either imputed genotype data or summary statistics generated as described in 398 the original GWASs. For sample details, see 
409
Immune disease datasets 410
To estimate the extent of genetic overlap between schizophrenia and immune diseases, 411 we obtained full GWAS or Immunochip summary statistics for 14 of the 19 immune diseases 412 (five immune diseases were not included in PRS analyses due to lack of available summary 413 statistics). We obtained publicly available summary statistics for ten immune diseases (see Table 2 ), because conditional 426 analyses reporting adjusted effect sizes of independent HLA variants were not available for all 427 immune diseases. In total there were 581 unique variants (563 non-HLA variants and 18 HLA We evaluated the association of these 581 variants with schizophrenia using previously 430 published association results for non-HLA (1) and HLA variants (11). We considered SNPs 431 associated with schizophrenia at p<8.6x10 -5 (Bonferroni correction for 581 tests, 563 non-HLA 432 and 18 HLA variants) to have pleiotropic effects. 
520
Power for PRS was evaluated using AVENGEME (62, 63), assuming disease and genetic 521 parameters detailed in S6 
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